From Medscape Oncology

Coverage from the

European Society for Medical Oncology (ESMO BCC) Breast Cancer Congress 2022

May 03 - 05, 2022; Berlin, Germany and Virtual/Online

May 03 - 05, 2022 Berlin, Germany and Virtual/Online

ESMO BCC 2022 Promising Antitumor Activity After One ADC Dose in Breast Cancer Early data suggest that the antibody drug conjugate patritumab deruxtecan increases antitumor activity in early-stage breast cancer after a single dose.
Medscape Medical News, May 5, 2022
ESMO BCC 2022 'No Discernible Benefit' Adding Nivolumab to ADC in Breast Cancer However, combining nivolumab with trastuzumab deruxtecan in advanced, pretreated breast cancer did demonstrate antitumor activity, new data show.
Medscape Medical News, May 5, 2022

Conference News

ESMO BCC 2022 Twenty Years and Counting: Tamoxifen Benefit in Breast Cancer
Medscape Medical News, May 11, 2022
ESMO BCC 2022 Uninformed Breast Cancer Patients Are Making Treatment Decisions
Medscape Medical News, May 11, 2022
ESMO BCC 2022 Promising Antitumor Activity After One ADC Dose in Breast Cancer
Medscape Medical News, May 5, 2022

ESMO BCC 2022 Misconceptions Remain on Gene Signature Use in Breast Cancer
Medscape Medical News, May 5, 2022
ESMO BCC 2022 'No Discernible Benefit' Adding Nivolumab to ADC in Breast Cancer
Medscape Medical News, May 5, 2022

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Popular News

The Impact of BRCA Status on Therapy Choices Drs Lidia Schapira and Nadine Tung discuss how BRCA status affects choosing therapy for patients with early-stage breast cancer.
Medscape Medical News, Apr 12, 2022
Recurrent DCIS Can Be Genetically Distinct From Primary Lesion In more than 10% of cases, when ductal carcinoma in situ recurs in the same breast, the new lesion is genetically district from the original lesion.
Medscape Medical News, Apr 11, 2022
Is This the Most Controversial Issue in Early Breast Cancer Tx? In an online poll over use of chemotherapy for premenopausal patients with early breast cancer, votes were split without consensus; debate on this issue continues.
Medscape Medical News, Mar 25, 2022